These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9704460)

  • 1. Complement and biocompatibility.
    Mollnes TE
    Vox Sang; 1998; 74 Suppl 2():303-7. PubMed ID: 9704460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility.
    Mollnes TE
    Exp Clin Immunogenet; 1997; 14(1):24-9. PubMed ID: 9187920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection.
    Dalmasso AP; Vercellotti GM; Platt JL; Bach FH
    Transplantation; 1991 Sep; 52(3):530-3. PubMed ID: 1716798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model.
    Scholz T; Solberg R; Okkenhaug C; Videm V; Gallimore MJ; Mathisen O; Pedersen T; Mollnes TE; Bergan A; Søreide O; Klintmalm GB; Aasen AO
    Perfusion; 2001 Jul; 16(4):285-92. PubMed ID: 11486847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The complement system in xenotransplantation.
    Dalmasso AP
    Immunopharmacology; 1992; 24(2):149-60. PubMed ID: 1473965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
    Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
    Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological effects on the complement system. Possibilities and limitations of anti-inflammatory therapy].
    Kirschfink M
    Dtsch Med Wochenschr; 1995 Aug; 120(31-32):1087-90. PubMed ID: 7641591
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces.
    Kopp R; Mottaghy K; Kirschfink M
    ASAIO J; 2002; 48(6):598-605. PubMed ID: 12455769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit.
    Moen O; Fosse E; Bråten J; Andersson C; Høgåsen K; Mollnes TE; Venge P; Kierulf P
    Perfusion; 1996 Mar; 11(2):113-23. PubMed ID: 8740352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
    Kirschfink M; Kovacs B; Mottaghy K
    Circ Shock; 1993 Jul; 40(3):221-6. PubMed ID: 8348684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits.
    Videm V; Mollnes TE; Garred P; Svennevig JL
    J Thorac Cardiovasc Surg; 1991 Apr; 101(4):654-60. PubMed ID: 2008104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting complement in therapy.
    Kirschfink M
    Immunol Rev; 2001 Apr; 180():177-89. PubMed ID: 11414360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation and cytokine production as consequences of immunological bioincompatibility of extracorporeal circuits.
    Jahns G; Haeffner-Cavaillon N; Nydegger UE; Kazatchkine MD
    Clin Mater; 1993; 14(4):303-36. PubMed ID: 10146611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
    Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
    Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation.
    Wendel HP; Ziemer G
    Eur J Cardiothorac Surg; 1999 Sep; 16(3):342-50. PubMed ID: 10554855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.
    Mollnes TE; Videm V; Riesenfeld J; Garred P; Svennevig JL; Fosse E; Hogasen K; Harboe M
    Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):21-6. PubMed ID: 1934602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
    Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
    Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in assay of complement function and activation.
    Harboe M; Thorgersen EB; Mollnes TE
    Adv Drug Deliv Rev; 2011 Sep; 63(12):976-87. PubMed ID: 21664392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.